KR960700696A - 정맥성 질환 치료에 유용한 5-하이드록시트립타민-2 수용체 길항물질 조성물(5-ht₂receptor antagonist compositions useful in treating venous conditions) - Google Patents

정맥성 질환 치료에 유용한 5-하이드록시트립타민-2 수용체 길항물질 조성물(5-ht₂receptor antagonist compositions useful in treating venous conditions) Download PDF

Info

Publication number
KR960700696A
KR960700696A KR1019950703438A KR19950703438A KR960700696A KR 960700696 A KR960700696 A KR 960700696A KR 1019950703438 A KR1019950703438 A KR 1019950703438A KR 19950703438 A KR19950703438 A KR 19950703438A KR 960700696 A KR960700696 A KR 960700696A
Authority
KR
South Korea
Prior art keywords
receptor antagonist
hydrochloride
piperazinyl
ethyl
amount
Prior art date
Application number
KR1019950703438A
Other languages
English (en)
Other versions
KR100278522B1 (ko
Inventor
엠. 새미어 애머
Original Assignee
엠. 새미어 애머
샘 애머 앤드 컴패니, 인코오포레이티드
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 엠. 새미어 애머, 샘 애머 앤드 컴패니, 인코오포레이티드 filed Critical 엠. 새미어 애머
Publication of KR960700696A publication Critical patent/KR960700696A/ko
Application granted granted Critical
Publication of KR100278522B1 publication Critical patent/KR100278522B1/ko

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Cardiology (AREA)
  • Dermatology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hospice & Palliative Care (AREA)
  • Vascular Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

본 발명은 치질, 정맥류 정맥 부전증 및 상처 같은 정맥성 질환의 치료에 유용한 5-HT2수용체 길항물질을 함유하는 조성물 및 이 조성물을 사용하여 상기 질환을 치료하는 것에 관한 것이다. 구체적으로, 본 발명은 상기 질환을 앓고 있는 인체 또는 동물을 치료하는데 치료 유효량으로 5-HT2수용체 길항물질을 사용하는 것을 포함한다. 5-HT2수용체 길항물질은 또한 예방용으로 투여할 수도 있다.

Description

정맥성 질환 치료에 유용한 5-하이드록시트립타민-2 수용체 길항물질 조성물(5-HT2RECEPTOR ANTAGONIST COMPOSITIONS USEFUL IN TREATING VENOUS CONDITIONS)
본 내용은 요부공개 건이므로 전문내용을 수록하지 않았음

Claims (18)

  1. 정맥성 질환 치료 또는 예방을 약제의 제조를 위한 5-HT2수용체 길항물질의 사용 방법.
  2. 약제가 담체중에 치료 허용량의 5-HT2수용체 길항물질을 함유하는 것을 특징으로 하는 정맥성 질환 치료 또는 예방용 약제.
  3. 정맥성 질환으로 고생하고 있거나, 이 질환에 걸리기 쉬운 환자에게 5-HT2수용체 길항물질을 치료 유효량으로 투여하는 것을 특징으로 하는, 치질, 정맥류 정맥, 정맥 부전증 또는 상처 같은 정맥성 질환의 치료 또는 예방 방법.
  4. 치질, 정맥류 정맥, 정맥 부전증 또는 상처의 치료 또는 예방을 위한 5-HT2수용체 길항물질의 사용 방법.
  5. 제1 내지 제4항 중 어느 한 항에 있어서, 상기 5-HT2수용체 길항물질이 2′[2-(1-메틸-2-피페리딜)에틸]신남아닐라이드 하이드로클로라이드; 2-[3-[4-(3-클로로페닐)-1-피페라지닐]프로필-5-에틸-2,4-디하이드로-4-(2-페녹시에틸)-3H-1,2,4-트리아졸-3-온 하이드로 클로라이드; 8-[4-[4-(1,2-벤즈이소트리아졸-3-일)-1-피페라지닐]부틸]-8-아자스피로[4,5]데칸-7,9-디온 하이드로클로라이드 또는 이들의 혼합물인 약제, 사용 방법 또는 치료 방법.
  6. 제1 내지 제5항중 어느 한 항에 있어서, 상기 정맥성 질환인 치질, 정맥류 정맥, 정맥 부전증 또는 상처인 약제, 사용 방법 또는 치료 방법.
  7. 피부에 허용가능한 담체중에 5-HT2수용체 길항물질을 함유하는 것을 특징으로 하는 국소용 조성물.
  8. 제7항에 있어서, 상기 5-HT2수용체 길항물질이 2′[2-(1-메틸-2-피페리딜)에틸]신남아닐라이드 하이드로클로라이드; 2-[3-[4-(3-클로로페닐)-1-피페라지닐]프로필-5-에틸-2,4-디하이드로-4-(2-페녹시에틸)-3H-1,2,4-트리아졸-3-온 하이드로 클로라이드; 8-[4-[4-(1,2-벤즈이소트리아졸-3-일)-1-피페라지닐]부틸]-8-아자스피로[4,5]데칸-7,9-디온 하이드로클로라이드 또는 이들의 혼합물인 국소용 조성물.
  9. 제7 또는 8항에 있어서, 상기 5-HT2수용체 길항물질의 양이 0.1 내지 20 중량%인 국소용 조성물.
  10. 제7 내지 제9항 중 어느 한 항에 있어서, 상기 5-HT2수용체 길항물질의 양이 0.5 내지 10 중량%인 국소용 조성물.
  11. 약학적으로 허용가능한 담체중에 5-HT2수용체 길항물질을 함유하는 것을 특징으로 하는 좌제.
  12. 제11항에 있어서, 상기 5-HT2수용체 길항물질이 2′[2-(1-메틸-2-피페리딜)에틸]신남아닐라이드 하이드로클로라이드; 2-[3-[4-(3-클로로페닐)-1-피페라지닐]프로필-5-에틸-2,4-디하이드로-4-(2-페녹시에틸)-3H-1,2,4-트리아졸-3-온 하이드로 클로라이드; 8-[4-[4-(1,2-벤즈이소트리아졸-3-일)-1-피페라지닐]부틸]-8-아자스피로[4,5]데칸-7,9-디온 하이드로클로라이드 또는 이들의 혼합물인 좌제.
  13. 제11 또는 제12항에 있어서, 상기 5-HT2수용체 길항물질의 양이 0.1 내지 20 중량%인 좌제.
  14. 제11 내지 13항 중 어느 한 항에 있어서, 상기 5-HT2수용체 길항물질의 양이 0.5 내지 10 중량%인 좌제.
  15. 허용가능한 담체중에 5-HT2수용체 길항물질을 함유하는 것을 특징으로 하는 상처 붕대.
  16. 제15항에 있어서, 상기 5-HT2수용체 길항물질이 2′[2-(1-메틸-2-피페리딜)에틸]신남아닐라이드 하이드로클로라이드; 2-[3-[4-(3-클로로페닐)-1-피페라지닐]프로필-5-에틸-2,4-디하이드로-4-(2-페녹시에틸)-3H-1,2,4-트리아졸-3-온 하이드로 클로라이드; 8-[4-[4-(1,2-벤즈이소트리아졸-3-일)-1-피페라지닐]부틸]-8-아자스피로[4,5]데칸-7,9-디온 하이드로클로라이드 또는 이들의 혼합물인 상처 붕대.
  17. 제15항 또는 제16항에 있어서, 상기 5-HT2수용체 길항물질의 양이 0.1 내지 20 중량%인 상처 붕대.
  18. 제15 내지 17항 중 어느 한 항에 있어서, 상기 5-HT2수용체 길항물질의 양이 0.5 내지 10 중량%인 상처 붕대.
    ※ 참고사항 : 최초출원 내용에 의하여 공개하는 것임.
KR1019950703438A 1992-01-09 1993-02-19 정맥성 질환 치료에 유용한 5-ht2 수용체 길항제 조성물 KR100278522B1 (ko)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US07/818,389 US5266571A (en) 1992-01-09 1992-01-09 Treatment of hemorrhoids with 5-HT2 antagonists
PCT/US1993/001485 WO1994018958A1 (en) 1992-01-09 1993-02-19 5-ht2 receptor antagonist compositions useful in treating venous conditions

Publications (2)

Publication Number Publication Date
KR960700696A true KR960700696A (ko) 1996-02-24
KR100278522B1 KR100278522B1 (ko) 2001-01-15

Family

ID=25225434

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1019950703438A KR100278522B1 (ko) 1992-01-09 1993-02-19 정맥성 질환 치료에 유용한 5-ht2 수용체 길항제 조성물

Country Status (11)

Country Link
US (2) US5266571A (ko)
EP (1) EP0684816B1 (ko)
KR (1) KR100278522B1 (ko)
AT (1) ATE258789T1 (ko)
AU (1) AU678149B2 (ko)
CA (1) CA2156481C (ko)
DE (1) DE69333413T2 (ko)
DK (1) DK0684816T3 (ko)
ES (1) ES2215990T3 (ko)
PT (1) PT684816E (ko)
WO (1) WO1994018958A1 (ko)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5364856A (en) * 1991-03-28 1994-11-15 Eli Lilly And Company 6-heterocyclic-4-amino-1,3,4,5-tetrahydrobenz[CD]indoles
US5266571A (en) * 1992-01-09 1993-11-30 Amer Moh Samir Treatment of hemorrhoids with 5-HT2 antagonists
US5780487A (en) * 1995-08-07 1998-07-14 Amer Moh Samir S-2'- 2-(1-methyl-2-piperidyl) ethyl! cinnamanilide
US5869059A (en) * 1996-01-16 1999-02-09 Mon's Tea Partnership Herbal composition for hemorrhoid treatment
GB9720270D0 (en) * 1997-09-25 1997-11-26 Pharmagene Lab Limited Medicaments for the treatment of migraine
DE10025644A1 (de) * 2000-05-24 2001-12-06 Lohmann Therapie Syst Lts Schmales bandförmiges transdermales therapeutisches System zur Applikation von Wirkstoffen direkt über dem arteriellen oder venösen Gefäßsystem
US6365198B1 (en) * 2001-01-28 2002-04-02 Gulf Pharmaceutical Industries Pharmaceutical preparation for the treatment of gastrointestinal ulcers and hemorrhoids
GB0306604D0 (en) * 2003-03-21 2003-04-30 Curidium Ltd Second medical use
US20050107867A1 (en) * 2003-11-17 2005-05-19 Taheri Syde A. Temporary absorbable venous occlusive stent and superficial vein treatment method
US7402320B2 (en) * 2004-08-31 2008-07-22 Vnus Medical Technologies, Inc. Apparatus, material compositions, and methods for permanent occlusion of a hollow anatomical structure
EP2586386B1 (en) * 2005-01-25 2018-10-31 Covidien LP Structure for permanent occlusion of a hollow anatomical structure
US20070082076A1 (en) * 2005-10-12 2007-04-12 Spencer Feldman Glutathione and coffee suppository
US9017361B2 (en) * 2006-04-20 2015-04-28 Covidien Lp Occlusive implant and methods for hollow anatomical structure
WO2012026914A1 (en) * 2010-08-23 2012-03-01 Sam Amer & Co., Inc. Methods and compositions for treating internal and external hemorrhoids
CN108440520A (zh) * 2018-03-12 2018-08-24 首都医科大学 苯并异噻唑类化合物及其制备方法和在治疗抑郁症方面的用途

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4000143A (en) * 1971-03-03 1976-12-28 Mead Johnson & Company Substituted piperidines
US3931195A (en) * 1971-03-03 1976-01-06 Mead Johnson & Company Substituted piperidines
US4064254A (en) * 1971-03-03 1977-12-20 Mead Johnson & Company Substituted piperidines therapeutic process and compositions
USRE30812E (en) * 1971-03-03 1981-12-01 Mead Johnson & Company Substituted piperidines therapeutic process and compositions
USRE30811E (en) * 1971-03-03 1981-12-01 Mead Johnson & Company Substituted piperidines therapeutic process and compositions
ES456574A1 (es) * 1977-03-07 1978-02-16 Rocador Sa Procedimiento de obtencion de pentametil-carbamato de quer- cetina.
US4335127A (en) * 1979-01-08 1982-06-15 Janssen Pharmaceutica, N.V. Piperidinylalkyl quinazoline compounds, composition and method of use
US4265887A (en) * 1979-12-11 1981-05-05 Breskman Joseph S Composition and method for treatment of hemorrhoids
US4342870A (en) * 1980-03-28 1982-08-03 Janssen Pharmaceutica N.V. Novel 3-(1-piperidinylalkyl)-4H-pyrido[1,2-a]pyrimidin-4-one derivatives
US4487773A (en) * 1981-03-16 1984-12-11 Mead Johnson & Company 1,2,4-Triazol-3-one antidepressants
US4338317A (en) * 1981-03-16 1982-07-06 Mead Johnson & Company Phenoxyethyl-1,2,4,-triazol-3-one antidepressants
US4411901A (en) * 1981-12-23 1983-10-25 Mead Johnson & Company Benzisothiazole and benzisoxazole piperazine derivatives
US4539318A (en) * 1984-06-04 1985-09-03 Merck & Co., Inc. Tertiary aminohydroxypropoxy substituted thiadiazoles, pharmaceutical compositions and use
CA1246074A (en) * 1984-12-05 1988-12-06 Albertus H.M.T. Van Heertum Derivatives of hydroxy- or amino-substituted (piperidinylalkyl)quinazolines
US4665075A (en) * 1984-12-05 1987-05-12 Janssen Pharmaceutica N.V. Derivatives of hydroxy- or amino-substituted (piperidinylalkyl)quinazolines
US4677104A (en) * 1985-05-06 1987-06-30 Bristol-Myers Company Antipsychotic fused-ring pyridinylpiperazine derivatives
US4626433A (en) * 1985-05-20 1986-12-02 Preparation Gold, Inc. Remedy for hemorrhoids
US4851423A (en) * 1986-12-10 1989-07-25 Schering Corporation Pharmaceutically active compounds
US5196405A (en) * 1987-07-08 1993-03-23 Norman H. Oskman Compositions and methods of treating hemorrhoids and wounds
IT8947616A0 (it) * 1989-02-06 1989-02-06 Verde Giancarlo Umberto Preparato per il trattamento e la cura delle emorroidi
US5234914A (en) * 1991-06-11 1993-08-10 Patent Biopharmaceutics, Inc. Methods of treating hemorrhoids and anorecial disease
IT1251144B (it) * 1991-07-30 1995-05-04 Boehringer Ingelheim Italia Derivati del benzimidazolone
US5266571A (en) * 1992-01-09 1993-11-30 Amer Moh Samir Treatment of hemorrhoids with 5-HT2 antagonists
US5403867A (en) * 1992-02-07 1995-04-04 Kaken Pharmaceutical Co., Ltd. Preparation for treating wounds or hemorrhoids

Also Published As

Publication number Publication date
ES2215990T3 (es) 2004-10-16
CA2156481C (en) 2004-05-11
AU678149B2 (en) 1997-05-22
EP0684816B1 (en) 2004-02-04
US5266571A (en) 1993-11-30
DE69333413T2 (de) 2004-12-02
DE69333413D1 (de) 2004-03-11
WO1994018958A1 (en) 1994-09-01
KR100278522B1 (ko) 2001-01-15
PT684816E (pt) 2004-06-30
EP0684816A1 (en) 1995-12-06
US5605902A (en) 1997-02-25
CA2156481A1 (en) 1994-09-01
AU3774893A (en) 1994-09-14
DK0684816T3 (da) 2004-06-14
ATE258789T1 (de) 2004-02-15

Similar Documents

Publication Publication Date Title
KR960700696A (ko) 정맥성 질환 치료에 유용한 5-하이드록시트립타민-2 수용체 길항물질 조성물(5-ht₂receptor antagonist compositions useful in treating venous conditions)
KR960701033A (ko) 효능있는 칼슘 길항 및 산화방지 활성을 모두 갖는 화합물, 및 세포보호제로서 그것의 사용방법(compounds having both potent calcium antagonist and antioxidant activity and use there of as cytoprotective agents)
KR950016745A (ko) 생리증상의 치료방법 및 이를 위한 조성물
EA200700232A1 (ru) Высокоселективные ингибиторы обратного захвата норэпинефрина и способы их применения
ATE259232T1 (de) Verwendung von dextromethorphan oder dextrorphan zur behandlung der harninkontinenz
DK0668863T3 (da) Quinuclidinderivat som substans P-antagonist
KR950016746A (ko) 비-펩티드 타키키닌 수용체 길항물질
KR970702251A (ko) 허혈성 질환에 기인하는 증상의 개선 또는 치료약 및 이에 유용한 화합물(Ameliorant or0 remedy for symptoms caused by ischemic diseases and compounds useful therefor)
WO1999043354A2 (en) Method for treating painful conditions of the anal region and compositions therefor
KR950701223A (ko) 항허혈성(Anti-ichemic)약물
Cooper Ketoprofen in oral surgery pain: a review
KR20010021854A (ko) 말초 작용성 항소양성 아편제
KR950016760A (ko) 치질 치료제
DK0966285T3 (da) Anvendelse af (+)mefloquin til behandling af malaria
IE872975L (en) Compositions for treating hypertension
KR910011807A (ko) 4-벤질-5-페닐-2,4-디히드로-3h-1,2,4-트리아졸-3-온 및 진경제로서의 그 의 용도
KR960703593A (ko) (R)-암로디핀에 의한 평활근 세포 이동의 억제 (Inhibition of Smooth Muscle Cell Migration by (R)-Amlodipine)
NO20022954L (no) Anvendelse av bioaktive metabolitter av gepiron for behandling av psykologiske forstyrrelser
KR960705791A (ko) 기억력 향상제로서 유용한 3-아릴-4-알킬 및 4,5-디알킬-4H-1,2,4-트리아졸(3Aryl-4-alkyl and 4,5-dialkyl-4H-1,2,4-triazoles useful as memory enhancers)
PT900082E (pt) Utilizacao de piridilpiperazina e pirimidilpiperazina para o fabrico de um medicamento para o tratamento de perturbacoes de toxicomania
US2312715A (en) Emulsion for burn treatment
KR900701270A (ko) 피리디닐메틸(술피닐 또는 티오)벤즈이미다졸을 사용한 인체 눈의 녹내장 및 관련 장해의 치료 방법
JP2807092B2 (ja) 静脈症状を治療する上で有用な５‐ｈｔ▲下２▼レセプター拮抗剤組成物
KR910011258A (ko) 녹내장의 치료방법
Amer et al. Treatment of hemorrhoids with 5-HT 2 antagonists

Legal Events

Date Code Title Description
A201 Request for examination
E902 Notification of reason for refusal
E701 Decision to grant or registration of patent right
GRNT Written decision to grant
FPAY Annual fee payment

Payment date: 20121009

Year of fee payment: 13

EXPY Expiration of term